Want to see KR:101140 full AI Analyst Report?

INBIOGEN CO., Ltd. (101140) Price & Analysis

― Followers

101140 Stock Chart & Stats

₩4775.00

₩80.00(1.70%)

Oct 28, 2026

―

Day’s Range― - ―

52-Week Range₩4,255.00 - ₩14,300.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.58K

Market Cap

₩47.68B

Enterprise Value₩60.32B

Total Cash (Recent Filing)₩2.34B

Total Debt (Recent Filing)₩4.05B

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4161.70

Shares Outstanding10,044,217

10 Day Avg. Volume1,212

30 Day Avg. Volume3,578

Financial Highlights & Ratios

PEG Ratio-0.28

Price to Book (P/B)0.67

Price to Sales (P/S)16.73

P/FCF Ratio-18.83

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative LeverageVery low leverage reduces the company’s dependence on creditors and limits interest-related pressure on future cash flows. This provides financial flexibility to continue pharmaceutical development and commercial activities, while making the balance sheet better able to absorb operating volatility.

Equity CushionA substantial equity base gives INBIOGEN a meaningful capital cushion relative to its assets and can help absorb losses or business volatility. That capitalization supports resilience over the next several quarters, even though current returns on the capital base remain weak.

Integrated Biopharma PlatformOperating across research, manufacturing, and sales gives the company exposure to multiple stages of the pharmaceutical value chain rather than relying solely on discovery. Its biologic and therapeutic portfolio also provides a platform for serving healthcare providers and distribution channels.

Bears Say

Persistent Cash BurnConsistently negative operating and free cash flow indicate that the core business is not currently funding itself through cash generation. Persistent outflows can constrain investment capacity, increase reliance on financing or asset resources, and weaken the durability of the business model.

Revenue And Gross Profit PressureRecent revenue contraction combined with negative gross profit points to pressure at the product and operating-cost level. If this persists, the company may struggle to achieve sustainable contribution from its medicine portfolio, limiting its ability to convert activity into profitable growth.

Unstable Earnings QualityLarge swings between reported profits and substantial losses make earnings power difficult to assess and reduce confidence in repeatable performance. The negative TTM return on equity further indicates that the company is not currently generating satisfactory returns from its substantial capital base.

101140 FAQ

What was INBIOGEN CO., Ltd.’s price range in the past 12 months?

INBIOGEN CO., Ltd. lowest stock price was ₩4255.00 and its highest was ₩14300.00 in the past 12 months.

What is INBIOGEN CO., Ltd.’s market cap?

INBIOGEN CO., Ltd.’s market cap is ₩47.68B.

When is INBIOGEN CO., Ltd.’s upcoming earnings report date?

INBIOGEN CO., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 20 days.

How were INBIOGEN CO., Ltd.’s earnings last quarter?

INBIOGEN CO., Ltd. released its earnings results on Aug 14, 2026. The company reported -₩147.772 earnings per share for the quarter.

Is INBIOGEN CO., Ltd. overvalued?

According to Wall Street analysts INBIOGEN CO., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does INBIOGEN CO., Ltd. pay dividends?

INBIOGEN CO., Ltd. does not currently pay dividends.

What is INBIOGEN CO., Ltd.’s EPS estimate?

INBIOGEN CO., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does INBIOGEN CO., Ltd. have?

INBIOGEN CO., Ltd. has 10,044,217 shares outstanding.

What happened to INBIOGEN CO., Ltd.’s price movement after its last earnings report?

INBIOGEN CO., Ltd. reported an EPS of -₩147.772 in its last earnings report. Following the earnings report the stock price went up 0.949%.

Which hedge fund is a major shareholder of INBIOGEN CO., Ltd.?

Currently, no hedge funds are holding shares in KR:101140

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

INBIOGEN CO., Ltd.

Headquartered in Pyeongtaek, South Korea, INBIOGEN Co., Ltd. is a footwear manufacturer and distributor founded in 1949. The company produces and sells shoes for children, youth, and adults, serving both the South Korean domestic market and international customers. Its extensive range of products is marketed under several popular brand names, including ARTIS, SPECS, WANGJA, NEOSPEC, and CHAMPION. INBIOGEN Co., Ltd. was formerly known as BTONE CO.,Ltd.